Skip to main content

Generics

  • Watson confirms generic OxyContin patent challenge

    MORRISTOWN, N.J. — Generic drug maker Watson Pharmaceuticals is hoping to become the first to market a version of a popular opioid painkiller.

    Watson said it had filed applications with the Food and Drug Administration seeking approval for a generic version of Purdue Pharma’s OxyContin (oxycodone) extended-release tablets in the 10-, 15-, 20-, 30-, 40-, 60- and 80-mg strengths.

  • NACDS president opines about the cost of medication nonadherence

    ALEXANDRIA, Va. — Looking to further communicate the important role pharmacy plays in the healthcare delivery system, the National Association of Chain Drug Stores president and CEO Steve Anderson ran an opinion column in a "Medication Non-Adherence" supplement published Monday by Mediaplanet and distributed in The Washington Post.

  • Report: State Medicaid programs can reap savings with increase in generic drug use

    WASHINGTON — Ten states could reap significant savings by increasing the use of generic drugs in their state Medicaid programs, the Generic Pharmaceutical Association said Monday in response to a report by the American Enterprise Institute, a conservative think tank.

    The report, “Overspending on Multi-Source Drugs in Medicaid,” by Alex Brill, identified states that overspend the most on their Medicaid programs, with California, Texas and Georgia topping the list.

  • Teva launches chewable birth control pill

    NORTH WALES, Pa. — Teva Pharmaceuticals has launched a chewable birth control pill, the generic drug maker said Friday.

    Teva announced the launch of Zeosa (norethindrone and ethinyl estradiol) tablets.

    The drug is chemically equivalent to Warner Chilcott’s Femcon Fe tablets and is available in the 0.4 mg/0.035 mg strength.

     

  • Court: Watson's generic Fentora infringes on branded counterpart

    MORRISTOWN, N.J. — A generic painkiller made by Watson Pharmaceuticals infringes a patent covering the branded version, a U.S. District Court ruled.

    Watson said Friday that the U.S. District Court for the District of Delaware decided that Watson’s generic version of Cephalon’s Fentora (fentanyl) buccal tablets infringes U.S. Patent No. 6,264,981, though the Food and Drug Administration had approved Watson’s version of the drug.

  • DAW Rxs drive up healthcare costs, study finds

    WOONSOCKET, R.I. — "Dispense-as-written" prescriptions are exacerbating medication nonadherence and costing the U.S. healthcare system billions of dollars, according to a new study by researchers at Harvard University, Brigham and Women's Hospital, and CVS Caremark.

  • Natco to sell retail pharmacy?

    HYDERABAD, India — Indian generic drug maker may end its five-year stint as a retail pharmacy operator, according to published reports.

    The Hindu Business Line reported Thursday that Natco was considering the sale of the SaveMart Pharmacy store in Lancaster, Pa.

  • Actavis' generic Valtrex OKed by FDA

    MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic treatment for shingles and genital herpes made by Actavis, the drug maker said Wednesday.

    The FDA approved Actavis’ valacyclovir hydrochloride tablets in the 500-mg and 1-g strengths.

    The drug is a generic version of GlaxoSmithKline’s Valtrex. Branded and generic forms of the drug had sales of about $1.5 billion in 2010, according to IMS Health.

X
This ad will auto-close in 10 seconds